Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Scot Ebbinghaus"'
Autor:
Kathryn Finch Mileham, Cassadie Moravek, Andrew S. Kennedy, Thomas S. Uldrick, E. Claire Dees, Caroline Schenkel, Scot Ebbinghaus, S. Percy Ivy, Jamie Renee Brewer, Atiqur Rahman, R. Donald Harvey, Vishal Bhatnagar, Elizabeth Ness
Publikováno v:
Clin Cancer Res
Purpose: Washout periods and concomitant medication exclusions are common in cancer clinical trial protocols. These exclusion criteria are often applied inconsistently and without evidence to justify their use. The authors sought to determine how was
Autor:
Xiaoyun Nicole Li, Thomas Jemielita, Cong Chen, S. Peter Kang, Meihua Wang, Chen Hu, Scot Ebbinghaus, Nageatte Ibrahim, James R. Anderson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-10 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background In oncology clinical development, objective response rate, disease control rate and early tumor size changes are commonly used as efficacy metrics for early decision-making. However, for immunotherapy trials, it is unclear whether these ea
Autor:
Julie A. Stone, Jiannan Kang, Kapil Mayawala, Jonathan W. Riess, Scot Ebbinghaus, Lokesh Jain, Keaven M. Anderson, David C. Turner, Andrew G. Robinson, Anna Georgieva Kondic, Vikram Sinha, Dinesh P. de Alwis, Edward B. Garon
Publikováno v:
Clinical Cancer Research. 24:5841-5849
Purpose: To investigate the relationship of pembrolizumab pharmacokinetics (PK) and overall survival (OS) in patients with advanced melanoma and non–small cell lung cancer (NSCLC). Patients and Methods: PK dependencies in OS were evaluated across t
Autor:
Marcelo Garrido, Valeriy Breder, Erluo Chen, Jennifer J. Knox, Scot Ebbinghaus, Thomas Yau, Bruno Daniele, Abby B. Siegel, Sadahisa Ogasawara, Yee Chao, Philippe Merle, Mohamed Bouattour, Julien Edeline, Ann-Lii Cheng, Ho Yeong Lim, Richard S. Finn, Masatoshi Kudo, Stephen L. Chan, Baek-Yeol Ryoo, Andrew X. Zhu
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(3)
PURPOSE Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). KEYNOTE-240 evaluated the efficacy and safety of pembrolizumab in this pop
Autor:
Jin Zhang, Jeffrey S. Weber, James R. Anderson, Anthony M. Joshua, Adil Daud, Scot Ebbinghaus, Richard F. Kefford, Richard W. Joseph, Amita Patnaik, Peter Hersey, Wen-Jen Hwu, Omid Hamid, Caroline Robert, Tara C. Gangadhar, Antoni Ribas, Scott J. Diede, F. Stephen Hodi, Hassane M. Zarour, Roxana S. Dronca, Jedd D. Wolchok
Publikováno v:
Journal of Clinical Oncology. 36:1668-1674
Purpose Pembrolizumab provides durable antitumor activity in metastatic melanoma, including complete response (CR) in about 15% of patients. Data are limited on potential predictors of CR and patient disposition after pembrolizumab discontinuation af
Autor:
José Baselga, Marianne Ewertz, Scot Ebbinghaus, Christine K. Gause, Joanne L. Blum, Antoinette R. Tan, Serafin Morales, Mary Beth Jones, Kumudu Pathiraja, Beverly Moy, Tufia C. Haddad, Ellie Im, Hope S. Rugo, Javier Cortes, David J. Mauro, Ahmad Awada, L Eaton, Eva Ciruelos, Kathryn J. Ruddy, Peter Vuylsteke
Publikováno v:
Breast cancer research and treatment, vol 163, iss 3
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Baselga, J, Morales, S M, Awada, A, Blum, J L, Tan, A R, Ewertz, M, Cortes, J, Moy, B, Ruddy, K J, Haddad, T, Ciruelos, E M, Vuylsteke, P, Ebbinghaus, S W, Im, E, Eaton, L, Pathiraja, K, Gause, C K, Mauro, D, Jones, M B & Rugo, H S 2017, ' A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer ', Breast Cancer Research and Treatment, vol. 163, no. 3, pp. 535–544 . https://doi.org/10.1007/s10549-017-4199-3
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Baselga, J, Morales, S M, Awada, A, Blum, J L, Tan, A R, Ewertz, M, Cortes, J, Moy, B, Ruddy, K J, Haddad, T, Ciruelos, E M, Vuylsteke, P, Ebbinghaus, S W, Im, E, Eaton, L, Pathiraja, K, Gause, C K, Mauro, D, Jones, M B & Rugo, H S 2017, ' A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer ', Breast Cancer Research and Treatment, vol. 163, no. 3, pp. 535–544 . https://doi.org/10.1007/s10549-017-4199-3
PurposeCombining the mTOR inhibitor ridaforolimus and the anti-IGFR antibody dalotuzumab demonstrated antitumor activity, including partial responses, in estrogen receptor (ER)-positive advanced breast cancer, especially in high proliferation tumors
Autor:
Adil Daud, Jeroen Elassaiss-Schaap, Richard F. Kefford, Jin Zhang, Jeffrey S. Weber, Andrea Marie Perrone, Amita Patnaik, Caroline Robert, F. Stephen Hodi, Peter Hersey, Wen-Jen Hwu, Antoni Ribas, Richard W. Joseph, Jedd D. Wolchok, Tara C. Gangadhar, Omid Hamid, S. Peter Kang, Dinesh P. de Alwis, Roxana S. Dronca, Anthony M. Joshua, Keaven M. Anderson, Scot Ebbinghaus
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 24, iss 20
Clinical Cancer Research
Clinical Cancer Research, 24(20), 4960–4967
Clinical Cancer Research
Clinical Cancer Research, 24(20), 4960–4967
Purpose: The purpose of this study was to assess the association of baseline tumor size (BTS) with other baseline clinical factors and outcomes in pembrolizumab-treated patients with advanced melanoma in KEYNOTE-001 (NCT01295827). Experimental Design
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d5259ec95070357aaab6d85752cf2a5
https://escholarship.org/uc/item/62m363dn
https://escholarship.org/uc/item/62m363dn
Autor:
Catherine Vezina, Jacek Toporski, Julia Glade-Bender, Steven G. DuBois, Susan L. Cohn, Alberto S. Pappo, Antonio Sergio Petrilli, Scott J. Diede, Theodore W. Laetsch, Margaret E. Macy, Kumudu Pathiraja, Hyoung Jin Kang, Lynley V. Marshall, Martin Ebinger, Navin R. Pinto, Elizabeth Fox, Scot Ebbinghaus, Wayne Nicholls, Michal Yalon-Oren, Birgit Geoerger
Publikováno v:
Ann Transl Med
Summary Background Pembrolizumab is approved for the treatment of advanced cancer in adults; however, no information is available on safety and efficacy in paediatric patients. We aimed to establish the recommended phase 2 dose of pembrolizumab and i
Autor:
Honghong Zhou, Caroline Robert, Georgina V. Long, Gil Bar-Sela, Christoph Hoeller, Christian U. Blank, Matteo S. Carlino, Dirk Schadendorf, Catherine Barrow, Antoni Ribas, Christian Caglevic, Adil Daud, Erika Richtig, Ahmed Tarhini, Erin Jensen, Pascal Wolter, Nageatte Ibrahim, Kenneth Emancipator, Marta Nyakas, Scot Ebbinghaus
Background Predictive biomarkers of patients likely to benefit from anti–programmed death 1 inhibitor therapy have clinical relevance. We examined whether line of therapy or tumour programmed death ligand 1 (PD-L1) expression affects the efficacy a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::379a23f5eaed8008bb5457e825ae223b
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85051002457
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85051002457
Autor:
Christian U. Blank, Antoni Ribas, Ana Arance, Scot Ebbinghaus, Honghong Zhou, James Larkin, Jean-Jacques Grob, Jacob Schachter, Matteo S. Carlino, Laurent Mortier, Adil Daud, Omid Hamid, Michal Lotem, Paul Lorigan, Catriona M. McNeil, Bart Neyns, Teresa M. Petrella, Georgina V. Long, Nageatte Ibrahim, Caroline Robert
Publikováno v:
Lancet (London, England). 390(10105)
Summary Background Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced melanoma. We present the final protocol-specified survival analysi